Celgene Prices $4.5 Billion of Senior Unsecured Notes
February 09 2018 - 7:30AM
Business Wire
Celgene Corporation (NASDAQ:CELG) today announced the successful
pricing of four series of senior unsecured notes for an aggregate
principal amount of $4.5 billion. Of these notes, $500 million will
mature in 2021 and will bear interest at an annual rate of 2.875
percent, $1.0 billion will mature in 2023 and will bear interest at
an annual rate of 3.25 percent, $1.5 billion will mature in 2028
and will bear interest at an annual rate of 3.90 percent and $1.5
billion will mature in 2048 and will bear interest at an annual
rate of 4.55 percent. The 2.875 percent notes due 2021, the 3.25
percent notes due 2023, the 3.90 percent notes due in 2028 and the
4.55 percent notes due in 2048 were priced to yield 2.891 percent,
3.303 percent, 3.942 percent and 4.587 percent, respectively.
Celgene expects to use the net proceeds from the offering to
finance a portion of the acquisition of Juno Therapeutics, Inc. and
to pay fees and expenses associated therewith and with the
offering. The offering is expected to close on February 20,
2018.
Citigroup Global Markets Inc., Deutsche Bank Securities Inc.,
J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner &
Smith Incorporated acted as joint book-running managers and
representatives of the several underwriters. A copy of the
preliminary prospectus supplement and the accompanying base
prospectus, which is filed as part of Celgene’s effective shelf
registration statement on Form S-3 filed on October 27, 2016 (File
No. 333-214279), may be obtained from any of the representatives by
calling Citigroup Global Markets Inc. at 1-800-831-9146, Deutsche
Bank Securities Inc. at 1-800-503-4611, J.P. Morgan Securities LLC
at 212-834-4533 and Merrill Lynch, Pierce, Fenner & Smith
Incorporated at 1-800-294-1322.
An electronic copy of the prospectus supplement and the
accompanying base prospectus may also be obtained at no charge at
the Securities and Exchange Commission’s website at
www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the notes described herein, nor
shall there be any sale of these notes in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the laws of such
jurisdiction. The offering of the notes will be made only by means
of a prospectus supplement and the accompanying base
prospectus.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180209005271/en/
Celgene
CorporationInvestors:908-673-9628investors@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2024 to Jul 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Jul 2023 to Jul 2024